FDA OKs First Liquid Biopsy for Lung Cancer Mutation FDA OKs First Liquid Biopsy for Lung Cancer Mutation

The blood-based genetic test is a companion diagnostic for erlotinib and for use in patients with non-small cell lung cancer. FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Related Links:

EML4-ALK fusion represents a bona fide oncogene driver and molecular target in non-small-cell lung cancer (NSCLC), and ALK-targeted therapy has demonstrated clear clinical utility for NSCLC patients with an ALK fusion gene aberration. First reported in 2007, EML4-ALK gene rearrangement was more prevalent in adenocarcinoma patients with a prevalence of approximately 2 –13% [1,2]. The recommended methods for detection of ALK rearrangement include Ventana D5F3 ALK immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH) and reverse transcription polymerase chain reaction (RT-PCR), all of which have shown hi...
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractSurgical intervention after induction chemoradiation is designed as curative treatment for resectable stage III/N2 non-small cell lung cancer. However, there is no definitive evidence to support this approach, possibly because successful treatment requires certain “arts”, such as proper patient selection, an appropriate induction regimen, and choice of the best surgical procedure. We review the previous reports and discuss our own experience to explore the appropriate strategy for patients with resectable stage III/N2 disease, and to identify the factors associated with successful surgical intervention....
Source: Surgery Today - Category: Surgery Source Type: research
ConclusionFLC and exposure to coal combustion have an important impact on the clinicopathological characteristics and gene fusion mode of NSCLC, particularly in cases of higher levels of carcinogens, and genetic susceptibility has a greater impact. Our findings may help evaluate the effect of FLC and coal exposure on the pathogenesis of lung cancer.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Opinion statementThe treatment of advanced non-small cell lung cancer (NSCLC) has evolved to include targeted therapy, immunotherapy as well as chemotherapy for selected patients in the first-line setting. Angiogenesis inhibitors have been used in combination with chemotherapy in the first-line and maintenance settings providing improved progression-free survival (PFS) and objective response rate (ORR), as well as overall survival (OS) in selected studies. Biologic rationale exists for combining anti-angiogenic agents with immunotherapy and targeted kinase inhibitors (TKIs). A recent study has demonstrated improved surviva...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion RASSF1A methylation in lung cancer tissue can serve as a prognostic factor of NSCLC. More studies are needed to uncover the underlying mechanisms. PMID: 30764677 [PubMed - as supplied by publisher]
Source: Biomarkers - Category: Research Tags: Biomarkers Source Type: research
In this study, we investigated the expression and functional role of lncRNA small nucleolar RNA host gene 20 (SNHG20) as well as its underlying mechanism in NSCLC. Our results showed that SNHG20 was significantly up-regulated in NSCLC tissues and cells. High SNHG20 expression was implicated with poor prognosis in NSCLC patients. Moreover, SNHG20 knockdown suppressed proliferation, migration and invasion, and induced apoptosis in NSCLC cells. Furthermore, SNHG20 could function as a competing endogenous RNA (ceRNA) to elevate ZEB2 and RUNX2 expression by sponging miR-154. Rescue assays revealed that miR-154 inhibition could ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Our study shows that retinoblastoma (RB1) mutation is associated with decreased overall survival in patients with locally advanced and advanced non small cell lung cancer. We also show thatRB1 mutation correlates with lack of response to immunotherapy. AbstractThe retinoblastoma gene (RB1) encodes the retinoblastoma (RB) pocket protein that plays an important role in cell cycle progression. Here we determine the frequency and prognostic significance ofRB1 mutation in non small cell lung cancer (NSCLC), restricting inclusion to Stage III and IV patients with linked genomic and clinical data. The primary outcome was median o...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Cardamonin, a natural chalcone compound, has been reported to exert anticancer effects in several cancers. However, the specific pharmacological actions of cardamonin on human non-small-cell lung cancer (NSCLC) and the potential mechanisms still remain obscure. Here, we investigated the antineoplastic role of cardamonin in NSCLC both in vitro and in vivo. The proliferation of five NSCLC cell lines was inhibited in a dose-dependent and time-dependent manner with cardamonin treatment. In A549 and H460 cells, cardamonin induced apoptosis by activating caspase-3, upregulating Bax, and downregulating Bcl-2. In addition, cardamo...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: PRECLINICAL REPORTS Source Type: research
In this study, nm23-H1 was down regulated in epithelial-mesenchymal transition (EMT) and stemness enhancement under cobalt chloride (CoCl2)-induced hypoxia in NSCLC cells. Moreover, knocking down of nm23-H1 by shRNA apparently promoted hypoxia induced EMT and stemness, which was entirely suppressed via over expression of nm23-H1. Mechanistically, the Wnt/β-catenin signaling pathway was found to participate in the nm23-H1-mediated process. Besides, XAV939 prohibited cell EMT and stemness which could be impaired by knocking down of nm23-H1, while stable transfection of nm23-H1 attenuated hypoxia phonotype induced by lit...
Source: Biological Chemistry - Category: Chemistry Tags: Biol Chem Source Type: research
Condition:   Non Small Cell Lung Cancer Interventions:   Other: Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation;   Procedure: Surgery Sponsor:   Shanghai 10th People's Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Genetics | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Tarceva